Vilazodone

Generic Name: Vilazodone

Brand Names: Viibryd

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₇N_₅O_₂

CAS Number: 163521-12-8

Unique Ingredient Identifier: S239O2OOV3

Background: Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors. Vilazodone may also be associated with less sexual dysfunction and weight gain. Vilazodone was given FDA approval on January 21, 2011.

Indication: 用于治疗成人重度抑郁症（MDD）。

Associated Conditions: Major Depressive Disorder (MDD)

Associated Therapies: -

Clinical Trials

Double-Blind Treatment of Major Depressive Disorder With Vilazodone

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vilazodone
Drug: Citalopram

First Posted Date: 2012-12-05

Last Posted Date: 2023-02-23

Lead Sponsor: University of Chicago

Target Recruit Count: 79

Registration Number: NCT01742832

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Study of Vilazodone to Treat Social Anxiety Disorder

Not Applicable

Conditions: Social Anxiety Disorder

Interventions: Drug: Vilazodone
Drug: Placebo

First Posted Date: 2012-10-23

Last Posted Date: 2014-01-20

Lead Sponsor: The Medical Research Network

Target Recruit Count: 30

Registration Number: NCT01712321

Locations: 🇺🇸
The Medical Research Network, LLC, New York, New York, United States

Vilazodone for Menopausal Hot Flashes

Not Applicable

Completed

Conditions: Hot Flushes

Interventions: Drug: placebo capsules
Drug: vilazodone

First Posted Date: 2012-09-07

Last Posted Date: 2015-01-14

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 36

Registration Number: NCT01680900

Locations: 🇺🇸
Dept OB/GYN, Mudd Professorship Suite, Philadelphia, Pennsylvania, United States

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder

Phase 3

Completed

Conditions: Generalized Anxiety Disorder

Interventions: Drug: Vilazodone
Drug: Placebo

First Posted Date: 2012-06-28

Last Posted Date: 2019-12-18

Lead Sponsor: Forest Laboratories

Target Recruit Count: 680

Registration Number: NCT01629966

Locations: 🇺🇸
Forest Investigative Site 038, Atlanta, Georgia, United States
🇺🇸
Forest Investigative Site 025, Boston, Massachusetts, United States
🇺🇸
Forest Investigative Site 016, Berlin, New Jersey, United States

and more 34 locations

Vilazodone Treatment for Marijuana Dependence

Phase 2

Completed

Conditions: Marijuana Dependence

Interventions: Drug: Placebo
Drug: Vilazodone

First Posted Date: 2012-04-10

Last Posted Date: 2016-08-10

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 76

Registration Number: NCT01574183

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States

Safety and Efficacy of Vilazodone in Major Depressive Disorder

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: Vilazodone

First Posted Date: 2012-04-09

Last Posted Date: 2015-05-18

Lead Sponsor: Forest Laboratories

Target Recruit Count: 1219

Registration Number: NCT01573598

Locations: 🇺🇸
Forest Investigative Site 016, Cromwell, Connecticut, United States
🇺🇸
Forest Investigative Site 034, Winter Park, Florida, United States
🇺🇸
Forest Investigative Site 006, Fort Myers, Florida, United States

and more 72 locations

Safety and Efficacy of Vilazodone in Major Depressive Disorder

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo to citalopram
Drug: Vilazodone
Drug: Placebo to vilazodone
Drug: Citalopram

First Posted Date: 2011-11-17

Last Posted Date: 2014-08-08

Lead Sponsor: Forest Laboratories

Target Recruit Count: 1162

Registration Number: NCT01473381

Locations: 🇺🇸
Forest Investigative Site 034, Cromwell, Connecticut, United States
🇺🇸
Forest Investigative Site 014, Allentown, Pennsylvania, United States
🇺🇸
Forest Investigative Site 060, Atlanta, Georgia, United States

and more 51 locations

Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Dose-matched placebo
Drug: Vilazodone

First Posted Date: 2011-11-17

Last Posted Date: 2014-04-03

Lead Sponsor: Forest Laboratories

Target Recruit Count: 518

Registration Number: NCT01473394

Locations: 🇺🇸
Forest Investigative Site 015, Lincoln, Rhode Island, United States
🇺🇸
Forest Investigative Site 013, Seattle, Washington, United States
🇺🇸
Forest Investigative Site 003, Encino, California, United States

and more 11 locations

Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: placebo
Drug: vilazodone

First Posted Date: 2008-05-23

Last Posted Date: 2010-10-27

Lead Sponsor: Forest Laboratories

Target Recruit Count: 481

Registration Number: NCT00683592

Locations: 🇺🇸
Pharmacology Research Institute, Newport Beach, California, United States
🇺🇸
Atlanta Institute of Medicine and Research, Atlanta, Georgia, United States
🇺🇸
Florida Clinical Research Center, Bradenton, Florida, United States

and more 5 locations

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: vilazodone

First Posted Date: 2008-03-26

Last Posted Date: 2017-09-25

Lead Sponsor: Forest Laboratories

Target Recruit Count: 616

Registration Number: NCT00644358

Locations: 🇺🇸
Gulfcoast Clinical Research, Fort Myers, Florida, United States
🇺🇸
Vince and Associates Clinical Research, Overland Park, Kansas, United States
🇺🇸
Pacific Clinical Research, Upland, California, United States

and more 32 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy